Herpes zoster (shingles) including ophth zoster Adult 1,000 mg tid for 7 days.
Immunocompetent & immunocompromised adult w/ renal impairment, CrCl ≥50 mL/min 1,000 mg tid,
30-49 mL/min 1,000 mg bid,
10-29 mL/min 1,000 mg once daily,
<10 mL/min 500 mg once daily.
Treatment of herpes simplex infections Immunocompetent adult & adolescent ≥12 yr 500 mg bid. Duration of therapy: Recurrent episodes: 3-5 days; initial episodes: 5-10 days.
Immunocompetent adult & adolescent w/ renal impairment, CrCl ≥30 mL/min 500 mg bid,
<30 mL/min 500 mg once daily.
Treatment of herpes labialis Immunocompetent adult & adolescent ≥12 yr 2 g bid for 1 day; 2nd dose given 12 hr (not <6 hr) after 1st dose.
Immunocompetent adult & adolescent w/ renal impairment, CrCl ≥50 mL/min 2,000 mg bid in 1 day,
30-49 mL/min 1,000 mg bid in 1 day,
10-29 mL/min 500 mg bid in 1 day,
<10 mL/min 500 mg as a single dose.
Prevention (suppression) of recurrences of herpes simplex infection Immunocompetent adult & adolescent ≥12 yr 500 mg once daily. Some patients w/ very frequent recurrences (eg, ≥10/yr) may gain additional benefit from 500 mg daily in divided doses (250 mg bid).
Immunocompromised adult 500 mg bid.
Immunocompetent adult & adolescent w/ renal impairment, CrCl ≥30 mL/min 500 mg once daily,
<30 mL/min 250 mg once daily.
Immunocompromised adult w/ CrCl ≥30 mL/min 500 mg bid,
<30 mL/min 500 mg once daily.
Reduction of transmission of genital herpes Immunocompetent heterosexual adult w/ ≤9 recurrences/yr 500 mg once daily given to infected partner.
Prophylaxis of CMV infection & disease Adult & adolescent ≥12 yr 2 g qid, initiated as early as possible post-transplant.
Adult & adolescent w/ CrCl ≥75 mL/min 2,000 mg qid,
50-<75 mL/min 1,500 mg qid,
25-<50 mL/min 1,500 mg tid,
10-<25 mL/min 1,500 mg bid,
<10 mL/min or on dialysis 1,500 mg once daily.
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
